-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Rapport Therapeutics, Maintains $66 Price Target

Benzinga·10/20/2026 16:34:08
Diffusion vocale
HC Wainwright & Co. analyst Douglas Tsao reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $66 price target.